<DOC>
	<DOCNO>NCT00002164</DOCNO>
	<brief_summary>To evaluate single dose pharmacokinetic profile Viracept pediatric powder formulation administer HIV infect exposed child infant ( 0 13 year age ) . An evaluation relative bioavailability pediatric powder formulation vs. standard tablet formulation old child ( 7 13 year age ) also conduct .</brief_summary>
	<brief_title>Phase I Study Safety , Tolerability , Pharmacokinetics Viracept HIV-1 Infected Children Exposed Infants</brief_title>
	<detailed_description>This study safety , tolerability pharmacokinetics Viracept pediatric powder formulation milk formula . First single dose administer . After patient population divide 4 group age , optimal dose determine group . This optimal dose give 3 time day 6 week primary observation period , plus optional 6 month extension . NOTE : During single dose portion study , patient may untreated may continue treatment current nucleoside antiretroviral therapy . During multiple dose administration Viracept , antiretroviral therapy intensify either add modify therapy . Antiretroviral therapy limit currently license include zidovudine , lamivudine , stavudine , didanosine zalcitabine .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Administration Pneumocystis carinii pneumonia prophylaxis accord CDC guideline permit . Patients must : For child &gt; = 3 month 13 year age : HIV infection . For child &lt; 3 month age : HIV infection exposure . Newborns must birth weight &gt; = 2500 gm . Absence screen serious unstable medical condition . Parent guardian able give write informed consent willing comply study requirement . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Children HIV associate malignancy require chemotherapy . Children clinical laboratory assessment great Grade 1 Toxicity Table time screen . Concurrent Medication : Excluded : Chemotherapy . Prior Medication : Excluded : Protease inhibitor . NOTE : Patients take investigational agent , immunomodulators , HIV1 vaccine , glucocorticoid unconventional therapy within one month prior day 0 study must evaluate determine impact treatment study . Patients may include excluded case case basis .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>May 1999</verification_date>
	<keyword>Biological Availability</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Dosage Forms</keyword>
	<keyword>Nelfinavir</keyword>
</DOC>